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MicroRNAs (miRNAs) are a class of recently identified noncoding RNAs that regulate gene expression at posttranscriptional level.
Due to the large number of genes regulated by miRNAs, miRNAs play important roles in many cellular processes. Emerging
evidence indicates that miRNAs are dysregulated in pituitary adenomas, a class of intracranial neoplasms which account for 10–15%
of diagnosed brain tumors. Deregulated miRNAs and their targets contribute to pituitary adenomas progression and are associated
with cell cycle control, apoptosis, invasion, and pharmacological treatment of pituitary adenomas. To provide an overview of
miRNAs dysregulation and functions of these miRNAs in pituitary adenoma progression, we summarize the deregulated miRNAs
and their targets to shed more light on their potential as therapeutic targets and novel biomarkers.
1. MicroRNAs
MicroRNAs (miRNAs) are a class of recently identified
noncoding RNAs. Mature miRNAs are short single-stranded
RNA molecules, approximately 19–23 nucleotides in length.
The miRNA sequence is encoded in a stem-loop structure
in the primary transcript that is cleaved in the nucleus by
the ribonuclease III enzyme Drosha to form the precur-
sor miRNA (pre-miRNA). The pre-miRNA is subsequently
exported to the cytoplasm by the exportin and then is cleaved
by another ribonuclease III enzyme Dicer to form mature
miRNA [1–3]. Mature miRNAs can regulate the expres-
sion of a large number of genes at the posttranscriptional
level. miRNA is partially complementary to the sequence of
miRNA recognition elements (MRE) in the 3󸀠 untranslated
regions (UTRs) of target mRNAs. The seed sequence with
seven nucleotides in miRNA determines the specificity of
mRNA targeting, whereas the remaining miRNA sequence
is supposed to stabilize the miRNA-target complex [4].
miRNA can inhibit translation of target mRNAs by blocking
protein translation machinery or by sequestering the mRNA
transcript away from ribosomal interaction. miRNA can
also induce target mRNA degradation in a similar way like
RNA interference [1, 5]. miRNAs have been identified in
a wide range of species, and computational analysis shows
that nearly 30% of protein-coding genes can be modulated
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by miRNAs [6]. In general, miRNAs negatively regulate the
expression of their targets. However, it is also reported that
miR-369-3p can upregulate the expression of its target, tumor
necrosis factor-𝛼 (TNF-𝛼) [7].
miRNAs have been demonstrated to play important
roles in many biological processes, such as cell cycle con-
trol, proliferation, apoptosis, differentiation, metabolism,
hemopoiesis, and development [8]. A rapidly growing body
of evidence shows that miRNAs also have comprehensive
functions in tumor progression. SomemiRNAsmay function
as oncogenes (also called oncomirs) while some miRNAs
are supposed to be tumor suppressors [9]. The importance
of miRNAs in cancer is highlighted by the fact that half of
all miRNA genes are located in cancer-associated regions or
fragile sites, which are frequently altered or deleted in cancer
[10].Many tumor types showuniquemiRNA signatures; thus,
miRNAs may be of use in cancer diagnosis and prognosis
[11, 12].
2. Pituitary Adenomas
Pituitary adenomas are usually benign intracranial neo-
plasms, accounting for 10–15% of diagnosed brain tumors
[13]. Pituitary adenomas can be derived from a single
mutant cell of five differentiated cell types within pituitary
gland: somatotropes, lactotropes, corticotropes, thyrotropes,
and gonadotropes, which, respectively, secrete growth hor-
mone (GH), prolactin (PRL), adrenocorticotrophic hor-
mone (ACTH), thyroid-stimulating hormone (TSH), and
gonadotropins (follicle-stimulating hormone (FSH) and
luteinizing hormone (LH)). According to the hormonal
activity, pituitary adenomas can be defined as “functioning,”
causing endocrine dysfunction such as Cushing’s disease
in ACTH-secreting pituitary adenomas, acromegaly in GH-
secreting pituitary adenomas, galactorrhea and amenorrhea
in PRL-secreting pituitary adenomas, and hyperthyroidism
in TSH-secreting pituitary adenomas. On the other hand,
nonfunctioning pituitary adenomas (NFA) do not give rise
to hormone hypersecretion [14].
Pituitary adenomas might be small lesions with slow
growth. However, some pituitary adenomas grow rapidly
and cause tumor mass effect, the local compressive effect
of large pituitary tumors on brain structures and cranial
nerves. They can also invade downwards into the paranasal
sinuses, laterally into the cavernous sinuses and upwards
into the parenchyma of the brain. Occasionally, malignant
pituitary carcinomas metastasize to distant locations in the
central nervous system, lymph nodes, liver, and other sites
throughout the body [13].
In recent years, some reports demonstrated that pituitary
adenomas have altered expression files ofmiRNAs.Neverthe-
less, the correlation and function of miRNAs and their target
genes in pathogenesis of pituitary adenomas remain largely
unknown. Only a small number of miRNAs with their target
genes in pituitary adenomas have been validated so far. In
this review, we summarize recent advances in the study of
miRNAs and their validated or potential targets in pituitary
adenomas and discuss the future perspectives.
3. MicroRNAs in Pituitary Adenomas
3.1. Altered miRNA Expression in Pituitary Adenomas. Aber-
rant expressions of miRNAs have been demonstrated so far
(Table 1). miR-15a and miR-16-1 are the first two miRNAs
shown to have differential expression in pituitary adenomas.
miR-15a and miR-16-1 genes are located at chromosome
13q14, a regionwhich is frequently deleted in pituitary tumors
[24]. Previous studies have suggested that the genes in this
locus may be responsible for the progression of pituitary
adenoma to a more aggressive form [25]. In 2005, miR-15a
and miR-16-1 were reported to have lower expression in both
GH-secreting and PRL-secreting pituitary adenomas than in
normal tissues, and their downregulation was correlated with
greater tumor volume and impaired secretion of p43, a potent
anticancer cytokine, suggesting that miR-15a and miR-16-1
may function as tumor suppressors and their inactivation
may contribute to tumor growth in pituitary adenomas
[26]. In another study on ACTH-secreting pituitary tumors,
miR-15a and miR-16 were also expressed at a lower level
[27], but no association between miRNAs expression and
tumor size was observed in this study. This is in accordance
with the result of a subsequent report which showed no
correlation between downregulation of miR-15a and GH-
secreting pituitary tumor size [28]. Mutations in miR-16-1
gene have been reported to be partially responsible for its
altered expression in chronic lymphocytic leukemia (CLL)
patients [29]. Thus, it is worth exploring whether there are
similar mutations in pituitary adenoma patients.
let-7 is one of the first members in the miRNA family. let-
7 family members are located at chromosomal regions that
are often altered or deleted in human tumors [10]. Down-
regulation of let-7 has been reported in breast, lung, colon,
and others cancers [30–33] and let-7 is considered a tumor
suppressor by targeting RAS oncogene [34]. Recently, some
studies revealed that high-mobility group A2 (HMGA2) is
negatively regulated by the let-7 miRNAs in vitro [35, 36].
HMGA2plays diverse roles inmany biological processes such
as embryogenesis, differentiation, and neoplastic transforma-
tion [37]. Overexpression of HMGA2 is a hallmark of various
tumors, including pituitary adenomas, and is associated with
highly malignancy [38, 39]. The transgenic mice with over-
expressedHMGA2 developed pituitary adenomas, indicating
that HMGA2 may be involved in pituitary tumorigenesis
[40]. In 2009, Qian et al. reported the clinical significance of
HMGA2 overexpression in pituitary adenomas [15]. HMGA2
was frequently upregulated in pituitary adenomas including
PRL, ACTH, FSH/LH, or null cell adenomas but relatively
rare in GH and mixed GH/PRL adenomas. The authors also
reported decreased expression of let-7 in pituitary adenomas.
Intriguingly, an inverse correlation betweenHMGA2 and let-
7 was confirmed in this study. HMGA2 overexpression and
the decrease of let-7 were significantly correlated with tumor
proliferation, growth, invasion, and tumor grade, which lead
to a hypothesis that let-7 may also function as a tumor
suppressor in pituitary adenomas by targeting HMGA2.
Decreased expression of let-7a in pituitary adenomas was
also reported in other studies [27, 41], suggesting the general
downregulation of let-7 in pituitary adenomas. On the other
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Table 1: MicroRNAs and their target genes in human pituitary adenomas.
miRNA Upregulated or downregulated Target genes Tumor type Reference
let-7 Downregulated HMGA2 PRL, ACTHFSH/LH [15]
miR-23b Downregulated HMGA2 GH, NFAFSH/LH [16]
miR-26a Upregulated PRKCD ACTH [17]
miR-26b Upregulated PTEN GH [18]
miR-34b Downregulated HMGA1, HMGA2 GH [19]
miR-107 Upregulated AIP GH, NFA [20]
miR-128 Downregulated BMI1 GH [18]
miR-128a Upregulated Wee1 NFA [21]
miR-130b Downregulated CCNA2 GH, NFAFSH/LH [16]
miR-140-5p Upregulated Smad3 NFA [22]
miR-155 Upregulated Wee1 NFA [21]
miR-200c Upregulated PTEN PRL [23]
miR-326 Downregulated HMGA2, E2F1 GH [19]
miR-432 Downregulated HMGA2 GH [19]
miR-516a-3p Upregulated Wee1 NFA [21]
miR-548c-3p Downregulated HMGA1, HMGA2 GH [19]
miR-570 Downregulated HMGA2 GH [19]
miR-603 Downregulated E2F1 GH [19]
hand, some other miRNAs such as miR-98 can also regulate
HMGA2 expression [42], indicating that HMGA2 may have
multiple miRNAs regulators. During pituitary development,
let-7b/c was proposed to operate with the RNA-binding
protein KSRP in a negative feedback loop, in which KSRP
induces the maturation of let-7b/c, and let-7b/c posttran-
scriptionally downregulates the expression of KSRP itself
[43].
As pituitary adenomas can be derived from differenti-
ated cell types within pituitary gland, different subtypes of
pituitary adenomas could display distinct miRNA profiles,
and these specific profiles might be useful to distinguish
pituitary adenoma subtypes. In 2007, a list of thirty miRNAs
differentially expressed in pituitary adenomas was generated
by microarray [41]. Seven miRNAs were upregulated and
twenty-three were downregulated. The most representative
ones were miR-212, miR-026a, miR-150, miR-152, miR-191,
and miR-192, which were upregulated in pituitary adenomas,
while miR-024-1 and miR-098 were downregulated in tumor
samples. Twenty-nine miRNAs were identified to be able
to predict pituitary adenoma histotype (ACTH-, GH-, PRL-
secreting adenomas, and NFA). For the limit of sample num-
bers, the authors only analyzed the association of deregulated
miRNAs and tumor diameter in theNFAgroup. FivemiRNAs
were upregulated (miR-140, miR-099a, miR-099b, miR-030b,
andmiR-030c) and only one (miR-138-2) was downregulated
in macroadenomas compared to microadenomas.
In 2009, Amaral et al. investigated the differential expres-
sion of some miRNAs in ACTH-secreting pituitary tumors.
In addition to the decrease of let-7a, miR-15a, and miR-
16, they also found underexpression of miR-21, miR-141,
miR-143, miR-145, and miR-150 in ACTH-secreting pituitary
adenomas compared with normal pituitary tissues [27].
Among these miRNAs, downregulation of miR-141 has been
reported in gastric cancer [44] and renal cell carcinoma
[45]. miR-143 expression was decreased in human lung
and colorectal cancers [46, 47] and was reported to inhibit
KRAS translation in colorectal cancer cell [48]. miR-145 was
downregulated in human breast, lung, and colorectal cancers
[30, 46, 47, 49]. miR-145 could regulate the expression of
various targets in different tumors: FSCN1 in esophageal
squamous cell carcinoma [50], OCT4, EGFR, and NUDT1
in lung adenocarcinoma [51, 52], and FLI1 in colon cancer
[53]. miR-143/145 cluster is a target of Jagged-1/Notch sig-
naling in vascular smooth muscle cells [54]. miR-150 was
overexpressed in hematopoietic progenitor/stem cells [55]
and was demonstrated to target NOTCH3 in human T-cell
development in a recent study [56].
Studies were conducted with the aim of investigating the
aberrant expression of miRNAs in GH-secreting pituitary
adenomas. In 2010, Mao et al. identified totally fifty-twomiR-
NAs to be differentially expressed in GH-secreting pituitary
adenomas. Nine of these miRNAs had altered expression
between macro- and microadenomas. miR-184, miR-524-
5p, miR-629, and miR-766 were upregulated, while miR-
124, miR-222, miR-32, miR-744, and miR-765 were down-
regulated [28]. In 2012, another set of miRNAs were identi-
fied to be differentially expressed in GH-secreting pituitary
adenomas [19]. Eighteen miRNAs, including miR-34b, miR-
326, miR-432, miR-548c-3p, miR-570, and miR-603, were
drastically and constantly downregulated in GH adenomas,
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whereas only miR-320 was significantly upregulated. miR-
34b and miR-548c-3p were demonstrated to regulate both
HMGA1 and HMGA2 expression, whereas miR-326, miR-
432, andmiR-570 target HMGA2 only. miR-326 andmiR-603
could decrease the expression of the E2 transcription factor
1, E2F1. Besides, miR-107 was found to be overexpressed in
GH-secreting and nonfunctioning pituitary adenomas and
inhibited the expression of pituitary tumor suppressor gene
aryl hydrocarbon receptor-interacting protein (AIP) [20].
Recently, Palumbo et al. identified 17 miRNAs which were
differentially expressed in GH-secreting pituitary tumors.
Specifically, five miRNAs (miR-26b, miR-26a, miR-212, miR-
107, and miR-103) were upregulated and twelve miRNAs
(miR-125b, miR-141, miR-144, miR-164, miR-145, miR-143,
miR-15b, miR-16, miR-186, let-7b, let-7a3, and miR-128) were
downregulated. miR-26b and miR-128 controlled pituitary
cell properties through regulation of their direct targets,
PTEN, and BMI1, respectively [18]. miR-26b also targeted
Lef-1 and increased Pit-1 expression in GH3 cells [57].
miRNAs are also dysregulated in nonfunctioning pitu-
itary adenomas (NFA). In 2011, Butz et al. analyzed miRNAs
expression in NFA and the signaling pathways altered in
these pituitary tumors [22]. Expressions of Smad3, Smad6,
Smad9,MEG, andDLK1were significantly decreased inNFA.
Through pathway analysis and in silico target prediction, a
specific subset of miRNAs was identified that may potentially
downregulate TGF-𝛽 signaling pathway in NFA. Five miR-
NAs predicted to target Smad3 (miR-135a, miR-140-5p, miR-
582-3p, miR-582-5p, and miR-938) were overexpressed, of
whichmiR-140-5p has already been validated to target Smad3
directly [58]. In addition, an inverse correlation between
tumor size and the expression of eighteen miRNAs was
observed. SixmiRNAs of them (miR-450b-5p,miR-424,miR-
503, miR-542-3p, miR-629, and miR-214) were significantly
underexpressed, while one miRNA (miR-592) was signifi-
cantly overexpressed in NFA compared to normal pituitary
tissues. In another study, miR-124a was the most upregulated
miRNA, and miR-31 was the most downregulated miRNA in
nonfunctioning pituitary adenomas [59].
In gonadotropin-secreting pituitary adenomas, a study
demonstrated that miR-10b was upregulated and miR-
503 was downregulated [59]. Furthermore, the integra-
tion and coordination of hormones and pituitary cells are
important for the regulatory function of pituitary tissues.
Gonadotropin-Releasing Hormone (GnRH) acts on pitu-
itary gonadotropes to stimulate LH and FSH synthesis and
secretion. GnRH induces expressions of miR-132 and miR-
212 in L𝛽T2 pituitary gonadotrope cells to regulate cellular
morphology and migration. The p250RhoGAP protein is a
downstream target of miR132/212 and its downregulation is
involved in the morphological change and migration altered
by GnRH [60].
3.2. Functional Association of miRNAs in
Pituitary Tumorigenesis and Progression
3.2.1. miRNAs and Cell Cycle in Pituitary Adenomas. It is
well known that the dysfunction of cell cycle control is
a critical step in initiation and progression of human cancers.
Some oncoproteins or tumor suppressors play important
roles in cell cycle control by interacting with critical cell cycle
regulators, such as cyclin, cyclin-dependent-kinase (CDK),
or cell cycle inhibitors. During tumor progression, the genes
involved in cell cycle control often have aberrant expression,
resulting in unlimited tumor cell growth [61]. Some reports
suggested that the deregulated miRNAs might also regulate
cell cycle of pituitary adenomas at the post-transcriptional
level (Figure 1).
Wee1 was described as a tumor suppressor to inhibit cell
cycle. Wee1 phosphorylates Cdk1 and inhibits its activity to
block cell cycle in G2/M checkpoint [62]. Wee1 was down-
regulated in GH-secreting and NFA pituitary adenomas.
miR-128a, miR-155, and miR-516a-3p target 3󸀠-UTR of Wee1,
and exogenous overexpression of these miRNAs inhibited
Wee1 expression [21]. miR-128a is a brain-enriched miRNA
and was reported to be decreased in pituitary adenomas
[41]. Its ectopic overexpression reduced neuroblastoma cell
motility and invasiveness [63], suggesting its tumor sup-
pressive role. miR-155 was reported as an oncomir in both
hemopoietic malignancies and solid tumors [64]. miR-516a-
3p was involved in glioblastoma development [65] and was
associated with progression of breast cancer [66]. These
miRNAs may take part in the regulation of cell cycle in
pituitary adenomas together with other related miRNAs.
HMGA2 is associated with the E1A-regulated transcrip-
tional repressor p120 (E4F), interfering with p120 (E4F)
binding to the cyclin A promoter. Ectopic expression of
HMGA2 resulted in the activation of cyclin A promoter
and induction of endogenous cyclin A expression. Moreover,
chromatin immunoprecipitation experiments showed that
HMGA2 was associated with cyclin A promoter only when
the gene was transcriptionally activated. These data indicate
cyclin A as a cellular target of HMGA2 and, for the first
time, lead to a mechanism of HMGA2-dependent cell cycle
regulation [67]. Thus, let-7, as a regulator of HMGA2, may
exert its effects in cell cycle control of pituitary adenomas
by targeting HMGA2. miR-23b and miR-130b, which were
reduced in GH, gonadotroph, and NFPA adenomas, were
demonstrated to target HMGA2 and cyclin A2, respectively.
Overexpression of miR-23b and miR-130b arrested the cells
in the G1 and G2 phase of the cell cycle [16].
Recently, a study revealed that miR-15a and miR-16-1
cluster could modulate prostate cancer by targeting multiple
genes, including cyclin D1 [68]. Regarding the deregulation
in pituitary adenomas, miR-15a and miR-16-1 may exert their
roles as tumor suppressors by regulating cell cycle. Expression
of miR-126 and miR-381 was decreased in GH-secreting
pituitary adenomas [28]. Previous study has shown that mir-
126 could modulate phosphatidylinositol 3-kinase (PI3K)
signaling by limiting the PI3K regulatory subunit beta (p85b).
Loss ofmiR-126would eliminate the check point and increase
PI3K signaling, which facilitate tumor growth during colon
carcinogenesis [69]. miR-145 was downregulated in GH-
secreting pituitary adenomas [28], which is in line with the
results in 11 samples of cortitropinomas [27]. The potential
targets of miR-145 include myc, kras, fos, yes, fli, cyclin D2,
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Figure 1: Functions of miRNAs as oncogenic and tumor suppressive genes in pituitary adenomas. (a) Upregulation of oncogenic miRNAs
(oncomiRs) in pituitary adenomas results in suppression of their target tumor suppressor genes (e.g., TP53, MEN1, and RB1). (b)
Downregulation of tumor suppressive miRNAs results in upregulation of their target oncogenes (e.g., Gsp, Ras, and Cyclin D1). The
consequence of oncomiRs and tumor suppressive miRNAs regulation in pituitary adenomas might involve aberrant proliferation, cell cycle
control, apoptosis, and invasiveness.
and MAPK transduction proteins [30], indicating that miR-
145 might function in cell cycle control by targeting multiple
genes. miR-503 was highly expressed in NFA and had a
negative correlation with tumor size [22]. miR-503 has been
validated to directly target cyclin D1 and is thought to be a
tumor suppressor [70]. Furthermore, an important potential
target of miR-503 is the cell cycle regulator CDC25.
miR-26b and miR-128 were found to directly regulate
PTEN and BMI1, respectively. Moreover, miR-128 regulated
PTEN expression and Akt activity in the pituitary tumor cells
by interfering with the binding of BMI1 to PTEN promoter
[18]. Since PTEN-Akt pathway plays important roles in cell
cycle control, miR-26b and miR-128 might regulate cell cycle
through PTEN-Akt pathway [71]. Moreover, miR-26a was
also overexpressed in ACTH-secreting pituitary adenomas
and plays an important role in cell cycle control by modu-
lating protein kinase C delta [17].
3.2.2. miRNAs and Apoptosis in Pituitary Adenomas. Apop-
tosis, the process of programmed cell death, is an important
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barrier for tumor cells. Duringmalignant transformation and
tumor progression, tumor cells have to escape this regulated
cell death to obtain an advantage in growth and expansion.
At the early stage of apoptosis, cells receive death signals, and
then the “apoptotic trigger” is controlled by pro- or antiapop-
totic members of B-cell lymphoma 2 (Bcl-2) family and other
regulatory proteins [72]. Accumulating evidence have shown
that miRNAs can regulate cancer cell apoptosis by targeting
Bcl-2 family or other apoptosis regulators (Figure 1).
miR-15a and miR-16-1 were demonstrated to induce
apoptosis by targeting Bcl-2 in CLL [73]. Bcl-2 is a founding
member of the Bcl-2 family, a family of antiapoptotic proteins
governing mitochondrial death signaling. Bcl-2 is frequently
overexpressed in many types of human cancers, including
carcinomas, lymphomas, and leukemias [74]. In CLL, some
other apoptosis related genes were identified to be targets of
miR-15a and miR-16-1 cluster, such as MCL1, which could
enhance cell survival by inhibiting apoptosis. Therefore, it is
possible that, in pituitary adenomas, miR-15a and miR-16-1
influence apoptosis by targetingmultiple antiapoptotic genes.
Besides, miR-214 and miR-629, two miRNAs overexpressed
in NFA and negatively correlated with tumor size, also
potentially target Bcl2 [22].
miR-21 was differentially expressed in ACTH-secreting
pituitary adenomas compared with normal pituitary tissues
[27]. miR-21 has been identified to be upregulated in human
breast, lung, colorectal and other cancers [30, 46, 49, 75]. Sup-
pression of miR-21 by antisense oligonucleotides or miR-21
knockdown was associated with increased apoptotic activity
and inhibition of tumor cell growth, probably by downreg-
ulating the target tumor suppressor genes [76]. miR-21 may
exert its function in apoptosis by targeting tumor suppressor
Pdcd4 [77] and PTEN [78]. Overexpression of PDCD4 was
able to result in apoptotic death [79], and PTEN can induce
apoptosis through phosphoinositol-3-kinase/Akt dependent
and independent pathways [80]. miR-21 is upregulated both
in vitro and in vivo by oncogenic Ras [81].
miR-212 is strongly upregulated in pituitary adenomas
[41]. Putative targets of miR-212 include death effector
domain-containing protein (DEDD), a protein involved in
apoptotic signaling [82], as well as other proteins participat-
ing in apoptosis. miR184 was markedly upregulated in GH-
secreting pituitary adenomas and was correlated with tumor
diameter [28]. Contrary to that, another study reported
that ectopic overexpression of miR-184 resulted in increased
apoptosis [83]. Study of Cheng et al. suggested that the
upregulated miR-150, miR-152, miR-191, and miR-192 may
also be involved in apoptosis [84].
miR-26b was found to be upregulated in GH-secreting
pituitary tumors and directly regulate PTEN.Therefore, miR-
26b is able to regulate apoptosis through PTEN-Akt pathway.
miR-200c, which has been characterized as a tumor suppres-
sor or oncogene in different cancers, also inhibited apop-
tosis in pituitary adenoma cells by targeting the PTEN/Akt
signaling pathway [23]. Intriguingly, a novel marine drug,
SZ-685C that was isolated from the secondary metabolites
of a mangrove endophytic fungus was reported to induce
apoptosis of MMQ pituitary tumor cells by downregulating
miR-200c [85].
TGF-𝛽 has been shown to inhibit proliferation and
induce apoptosis in HP75 cells, a cell line derived from a
clinically NFA [86]. Thereby, the miRNAs targeting TGF-𝛽
signaling (miR-135a, miR-140-5p, miR-582-3p, miR-582-5p,
and miR-938) may have effects in apoptosis [22]. However,
as TGF-𝛽 can also promote cancer cell invasion by inducing
Epithelial-Mesenchymal Transition (EMT) [87], it is rational
to conclude that miRNAs targeting TGF-𝛽 pathway may
suppress invasion and metastasis by blocking EMT, as miR-
300 does in human epithelial cancer [88].Therefore, miRNAs
that regulate TGF-𝛽 pathway play controversial roles in
tumor initiation and progression. Deregulation of BMI1 has
been revealed to affect apoptosis; thus, miR-128, which was
downregulated in GH-secreting pituitary tumors, could also
affect apoptosis by directly regulating BMI1 [18]. These data
together lead to the hypothesis that many miRNAs may
function in a network to regulate apoptosis in pituitary
adenomas.
3.2.3. miRNAs and Invasion or Metastasis of Pituitary Ade-
nomas. Invasion and metastasis are critical lethal factors
for malignant cancer. Although invasion and metastasis
are rare in pituitary tumors, studies provide some clues of
miRNAs’ function in pituitary tumor invasion andmetastasis
(Figure 1).
Significant correlation between HMGA2 overexpression
and tumor cell invasion has been detected in breast cancer
and gastric cancer [89, 90]. In oral squamous cell carci-
nomas, strong staining of HMGA2 and loss of E-cadherin
expression were observed at the invasive front of tumor
[91]. Previous studies also demonstrated that tumor-specific
downregulation of E-cadherin and H-cadherin was related
to invasiveness of pituitary adenoma [92]. HMGA2 may
be involved in tumor cell invasion due to its association
with epithelial-mesenchymal transition that facilitates tumor
cell invasion. Since let-7 regulates HMGA2 expression in
pituitary adenomas, let-7 may also take a role in pituitary
adenoma invasion. In Amaral et al.’s study, although no
association between miRNAs expression and tumor size was
observed, the patients with ACTH-secreting pituitary tumors
expressing reduced miR-141 had more chance of remission
after transsphenoidal surgery, suggesting that miR-141 may
regulate pituitary genes involved in tumor growth and local
invasion [27]. PTTG protein 1 is a target of both miR-126
and miR-381, which were downregulated in GH-secreting
pituitary adenomas [28]. PTTG is overexpressed in most
pituitary adenomas and is involved in tumor invasion [93].
Therefore, miR-126 and miR-381 might regulate pituitary
adenoma invasion by targeting PTTG.
Aggressive pituitary adenomas and carcinomas fre-
quently have a deletion in regions near the RB gene [94, 95].
In 2010, Stilling et al. investigated the expression of miRNAs
in pituitary carcinomas [96]. In one case, ACTH carcinoma
had metastatic carcinomas in three sites. More miRNAs
were deregulated between pituitary adenomas and normal
pituitaries compared to carcinomas and normal pituitaries.
In pituitary carcinomas compared to ACTH adenomas, miR-
122 andmiR-493were upregulated, and, in all threemetastatic
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sites of ACTH carcinomas, miR-122 expression wasmarkedly
increased.
Recently, Palumbo et al. identifiedmiR-26b to be upregu-
lated andmiR-128 to be downregulated in GH-secreting pitu-
itary tumors [18]. Inhibition of miR-26b and overexpression
of miR-128 suppressed colony formation and invasiveness of
pituitary tumor cells. Interestingly, the inhibition of miR-26b
and overexpression of miR-128 had a synergistic effect on
suppressing the tumorigenicity and invasiveness of pituitary
tumors. Since deregulation of PTEN and BMI1 correlates
with the invasive and metastatic phenotype of several human
cancer types [97, 98], it is possible that miR-26b and miR-
128 regulate invasiveness of pituitary tumor cells by directly
targeting PTEN and BMI1, respectively. Although metastatic
pituitary carcinomas are rare, these data suggest that altered
expression ofmiRNAsmay provide diagnostic information to
distinguish pituitary adenomas and carcinomas before they
metastasize.
3.2.4. miRNAs and Pharmacological Treatment of Pituitary
Adenomas. The symptoms of mass effect and hormonal
hypersecretion caused by pituitary adenomas could be
reversed by surgical resection or debulking of the adenoma,
radiotherapy, or medical treatment. Medical treatment is the
primary choice for prolactinomas and the secondary option
for acromegaly, Cushing’s disease, gonadotropin-secreting
tumours, and TSH-secreting adenomas [99]. Some studies
provide evidence that miRNAs were differentially expressed
before and after pharmacological treatment, and the altered
miRNA profile could provide useful information of respon-
siveness of pituitary adenomas patients to pharmacological
treatment (Figure 1).
In 2007, a microarray was carried out to analyze the
miRNA profiles in pituitary adenomas and normal pituitary
samples. To elucidate whether miRNAs profile is altered by
pharmacological treatment, differentially expressed miRNAs
were identified in NFA from patients with pharmacological
treatment or patients without treatment [41]. Six miRNAs
were found to be differentially expressed: miR-29b, miR-
29c, and miR-200a were upregulated, while miR-134, miR-
148, andmiR-155were downregulated after treatment. Cluster
analysis showed clear distinction between pharmacological
treated and nontreated NFA. Thus, the miRNA expression
could differentiate treated patient samples from nontreated
patient samples.
In 2010, another study aimed to identify altered expres-
sion of miRNAs in GH-secreting pituitary adenomas [28].
Fifteen pituitary adenomas patients were treated with lan-
reotide for four months before surgery, while six patients did
not receive any presurgical medical treatments. Patients with
>50% reduction of GH secretion after lanreotide treatment
were considered somatostatin analogs (SSA) responders,
while patients with <50% GH secretion were considered
SSA nonresponders [100]. Thirteen miRNAs were differen-
tially expressed between GH-secreting pituitary adenomas
from patients with lanreotide treatment and those without
treatment. Eight miRNAs (miR-183, miR-193a-5p, miR-222,
miR-516b, miR-524-5p, miR-601, and miR-629, 99b) were
upregulated and five miRNAs (miR-124, miR-32, miR-574-
5p, miR-744, and miR-96) were downregulated. Moreover,
seven miRNAs were differentially expressed between SSA
responders and SSA nonresponders. Putative targets of these
miRNAs are mainly IGFBP family members, IGFALS, SCP1,
and matrix metalloproteinase-9.
4. Conclusion and Future Perspectives
Accumulating evidence demonstrates that a large number of
miRNAs have altered expression in pituitary adenomas, and
thesemiRNAsmay play important roles in tumor progression
by targeting multiple genes. The molecular mechanism of
the regulation of miRNAs in pituitary adenomas is still a
mystery. Some proofs indicate that genetic or epigenetic
alterations may contribute to the deregulated expression of
miRNAs. For example, mutations in the miR-16-1 gene have
been reported to be partially responsible for its aberrant
expression in CLL patients [29], and expressions of miR-
124 and miR-203 are decreased because of CpG methylation
[101]. Some miRNAs have been demonstrated to target
multiple genes, indicating that they may have different roles
in pituitary tumors. On the other hand, a gene involved in
pituitary adenomas progression can be modulated by more
than one miRNA. Therefore, the miRNAs and their targets
could regulate pituitary adenomas progression in a complex
network.
Advances in the technology to investigate miRNAs make
it easier and faster to explore more exactly the roles of
miRNAs in pituitary adenomas. As some miRNAs signatures
can be used to distinguish pituitary adenomas and normal
pituitaries and even subtypes of pituitary tumors, it is also
possible to develop miRNA based diagnosis and therapies of
pituitary adenomas.The knowledge of pituitary pathogenesis
is still limited. Continuing study onmiRNAs and their targets
will shed more light on mechanisms of pituitary adenomas.
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